Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.70 |
| ▸ | MAPK13 | O15264 | 17/20 | 0.70 |
| ▸ | MAPK12 | P53778 | 17/20 | 0.70 |
| ▸ | MAPK11 | Q15759 | 17/20 | 0.70 |
| ▸ | RAF1 | P04049 | 11/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.70 |
| ▸ | GCGR | P47871 | 6/20 | 0.67 |
| ▸ | TEK | Q02763 | 1/20 | 0.63 |
| ▸ | BRAF | P15056 | 3/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.58 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11633700 | 0.93 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL5183702 | 0.90 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL28397209 | 0.89 | MAPK13 (0.71) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL5194917 | 0.88 | TEK (0.66) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL17002231 | 0.88 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL6468974 | 0.86 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL6466301 | 0.85 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL2949385 | 0.83 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL7228717 | 0.83 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL5613054 | 0.83 | MAPK14 (0.74) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678163-B1 | NOVEL IMIDAZOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2009-01-07 | — | — | EP | disclosed |
| EP-1499577-B1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-7169781-B2 | Imidazole derivatives and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7144889-B2 | Triarylimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1678163-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-12 | — | — | EP | disclosed |
| EP-1675848-A1 | NOVEL TRIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-05 | — | — | EP | disclosed |
| US-6946471-B2 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050113342-A1 | Novel imidazole derivatives and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005040153-A1 | NOVEL TRIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005040154-A1 | NOVEL IMIDAZOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085473-A1 | Novel triarylimidazoles | HOFFMANN-LA ROCHE INC. | 2005-04-21 | — | — | US | disclosed |
| EP-1499577-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | BRANDT MICHAEL | 2004-10-28 | — | — | US | disclosed |
| US-6790852-B2 | HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003087026-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085473-A1 | Novel triarylimidazoles | AURKAIP1, GLS2, GOT2 | MAPK14 2514/4885MAPK13 2770/4885MAPK12 3059/4885 |
| US-20050113342-A1 | Novel imidazole derivatives and their use as pharmaceutical agents | TUBB6, ABCB1, SDHA | MAPK14 1441/4885MAPK13 1842/4885MAPK12 2452/4885 |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | CYP2D6, CYP2F1, CYP1A2 | MAPK14 3521/4885MAPK13 3905/4885MAPK12 3572/4885 |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | CYP2D6, CYP1A2, CYP2F1 | MAPK14 3251/4885MAPK13 3695/4885MAPK12 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.